All HHS Contracts — July 20, 2026

Leidos Biomedical Research Inc. received a $4.81B contract from HHS, representing a massive, likely multi-year obligation that provides revenue visibility and underscores the company's entrenched position in biomedical research support.

Leidos Biomedical's $4.81B award represents 100% of the analyzed contract value, creating extreme revenue concentration risk for the company's biomedical segment if this contract faces re-compete or budget cuts.

The contract's pricing structure is unknown; if it is cost-plus, Leidos bears performance risk without fixed profit margins. The lack of competition signal also raises protest risk from competitors.

Leidos Biomedical's deep HHS relationship could be leveraged to win adjacent DOD biomedical research contracts, especially as the military invests in pandemic preparedness and biodefense.

HHS awarded a single $4.81B contract to Leidos Biomedical, indicating a preference for long-standing, specialized contractors in high-complexity biomedical support rather than competitive bidding.

{"entity"=>"Leidos Holdings Inc. (LDOS)", "reason"=>"This $4.81B HHS contract is a material revenue contributor; any re-compete, protest, or budget cut would directly impact LDOS stock.", "trigger"=>"HHS budget request for FY2027, contract modification disclosures, or GAO protest decision"}

{"entity"=>"HHS Biomedical Research Contracting", "reason"=>"The award signals continued HHS spending on biomedical research support, which could benefit other contractors like Battelle or MRIGlobal.", "trigger"=>"HHS solicitation for similar support services or task order awards"}